New hope for waitlisted patients addicted to opioids

December 6, 2017

As the opioid crisis continues to escalate, the number of people who need treatment for their dependency on heroin or prescription pain killers far exceeds the capacity of available treatment programs. People seeking treatment can wait months or even years for spots in clinics or with certified doctors—and while they wait, they risk becoming infected with HIV or hepatitis, as well as dying from an overdose.

Dr. Stacey Sigmon and her team at the University of Vermont's College of Medicine have developed a new intervention for reducing these risks among opioid-dependent people who are stuck on waitlists. The group recently completed a randomized pilot study assessing the feasibility of an interim dosing treatment and found it reduced illicit opioid use and injection drug use among waitlisted patients.

Instead of requiring frequent trips to a doctor or clinic, Dr. Sigmon's approach combines buprenorphine, an effective medication for treating opioid use disorder, with a computerized dispenser that provides only a single dose each day, to be taken at home. The device is equipped with locks and alarms to prevent tampering and ensure that the medication is not misused. The protocol also includes automated phone-based monitoring and random call-back visits for urine testing and pill counts. This regimen allows patients to start potentially life-saving medication immediately, while waiting for access to a community treatment program that includes more comprehensive counseling and other services.

Results from the 12-week study showed that waitlisted, opioid-dependent individuals receiving the interim buprenorphine were significantly better at abstaining from illicit opioid use, as proven by urine tests, compared to those who didn't receive the experimental treatment.

The effectiveness of the interim buprenorphine treatment will soon be the subject of a larger trial, with a focus on testing the treatment in more rural, underserved communities struggling with and limited treatment capacity. In the current, overburdened drug treatment system, Dr. Sigmon's interim therapy could help protect patients from the potentially fatal dangers of illegal use by safely and responsibly providing while they await more intensive .

Explore further: Team reports on study of waitlisted opioid-dependent adults

Related Stories

Team reports on study of waitlisted opioid-dependent adults

December 21, 2016
In rural states like Vermont, opioid-dependent adults desperate for treatment often find themselves stuck on a wait list, sometimes for eight months or more, increasing their risk of continuing to use illicit opioids, contract ...

Police referral without arrest lets opioid abusers seek help

December 27, 2016
(HealthDay)—A direct referral program and use of an interim buprenorphine regimen can be beneficial for encouraging individuals with an opioid-use disorder to seek help, and for reducing drug-related risks, according to ...

Extended-release naltrexone promising for opioid dependence

October 19, 2017
(HealthDay)—Extended-release naltrexone is noninferior to buprenorphine-naloxone for maintaining short-term abstinence from heroin and other illicit substances, according to a study published online Oct. 18 in JAMA Psychiatry.

FDA approves once-monthly injection for opioid addiction

December 4, 2017
(HealthDay)—Sublocade, a once-monthly injection of buprenorphine to treat opioid use disorder, has been approved by the U.S. Food and Drug Administration.

Clinical trial looks at tramadol for opioid withdrawal

July 12, 2017
A randomized clinical trial published by JAMA Psychiatry compared tramadol extended-release with clonidine and buprenorphine for the management of opioid withdrawal symptoms in patients with opioid use disorder in a residential ...

Medicaid patients continue high prescription opioid use after overdose

August 22, 2017
Despite receiving medical attention for an overdose, patients in Pennsylvania Medicaid continued to have persistently high prescription opioid use, with only slight increases in use of medication-assisted treatment, according ...

Recommended for you

Drug for spinal muscular atrophy prompts ethical dilemmas, bioethicists say

December 11, 2017
When the Food and Drug Administration approved the first drug for people with spinal muscular atrophy a year ago, clinicians finally had hope for improving the lives of patients with the rare debilitating muscular disease. ...

FDA's program to speed up drug approval shaved nearly a year off the process

December 7, 2017
Speeding the pace at which potentially lifesaving drugs are brought to market was a rallying cry for Donald Trump as a candidate, and is a stated priority of his Food and Drug Administration commissioner, Dr. Scott Gottlieb. ...

Dangers of commonly prescribed painkillers highlighted in study

December 6, 2017
Commonly prescribed painkillers need to be given for shorter periods of time to reduce the risk of obesity and sleep deprivation, a new study has revealed.

Viagra goes generic: Pfizer to launch own little white pill

December 6, 2017
The little blue pill that's helped millions of men in the bedroom is turning white. Drugmaker Pfizer is launching its own cheaper generic version of Viagra rather than lose most sales when the impotence pill gets its first ...

Surgery-related opioid doses can drop dramatically without affecting patients' pain

December 6, 2017
Some surgeons might be able to prescribe a third of opioid painkiller pills that they currently give patients, and not affect their level of post-surgery pain control, a new study suggests.

Four-fold jump in deaths in opioid-driven hospitalizations

December 4, 2017
People who end up in the hospital due to an opioid-related condition are four times more likely to die now than they were in 2000, according to research led by Harvard Medical School and published in the December issue of ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.